Savara Inc. (NASDAQ:SVRA) is one of the best US stocks under $10 to invest in, with H.C. Wainwright raising the price target to $5.00 and upgrading the stock from Neutral to Buy. The company’s optimism stems from an agreement with the FDA on CMC data requirements.

During a Type A meeting, Savara Inc. (NASDAQ:SVRA) resubmitted a BLA for Molbreevi after being refused a File letter. Analysts anticipate improved results with the BLA set to be resubmitted in December, showcasing potential growth for the company.

Savara Inc. (NASDAQ:SVRA) recently changed drug substance manufacturers to Fujifilm Diosynth Biotechnologies, a move seen as crucial for the company’s future success. Many view this as a pivotal moment for Savara Inc., positioning them for potential growth and success.

Established in 2007, Savara Inc. (NASDAQ:SVRA) is a Pennsylvania-based clinical-stage biopharmaceutical company focused on rare respiratory diseases. The company is dedicated to developing innovative therapies to enhance the quality of life for individuals affected by these conditions.

Read more at Yahoo Finance: Savara Inc. (SVRA) Upgraded to Buy After FDA CMC Breakthrough